GREEN BAY, Wis.--(BUSINESS WIRE)--Integrative Therapeutics, Inc., (ITI) the manufacturer and distributor of highly efficacious, natural medicines, sees the abrupt halt of the Pfizer clinical trials of torcetrapib as a harsh warning to pharmaceutical companies looking to develop synthetic drugs that increase HDL by suppressing cholesteryl ester transfer protein (CETP). The new drug trial was stopped when it resulted in over 50% more deaths than the control group, raising questions about the safety of these pharmaceutical interventions.
